{
    "clinical_study": {
        "@rank": "102363", 
        "arm_group": [
            {
                "arm_group_label": "Healthy volunteers low dose", 
                "arm_group_type": "Experimental", 
                "description": "MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days."
            }, 
            {
                "arm_group_label": "Healthy volunteers high dose", 
                "arm_group_type": "Experimental", 
                "description": "MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days."
            }, 
            {
                "arm_group_label": "Glaucoma patients", 
                "arm_group_type": "Experimental", 
                "description": "MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo eye drops, 1-3 drops three times per day, duration: 16 days."
            }
        ], 
        "brief_summary": {
            "textblock": "-  To assess the safety and tolerability of repeat dose topical administration of\n           MRZ-99030 Ophthalmic Solution with ascending doses in healthy subjects (stage 1) and\n           glaucoma subjects (stage 2).\n\n        -  To assess plasma pharmacokinetics and urine concentration of MRZ- 99030 and its\n           metabolite MRZ-9499 after single and repeat dose topical administration of MRZ-99030\n           Ophthalmic Solution."
        }, 
        "brief_title": "Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers and Glaucoma Patients", 
        "condition_browse": {
            "mesh_term": "Glaucoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For stage 1:\n\n        - Healthy volunteers\n\n        For stage 2:\n\n        - Glaucoma patients\n\n        Exclusion Criteria:\n\n        For stage 2:\n\n        - Any relevant eye disease other than glaucoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714960", 
            "org_study_id": "MRZ99030_1001_1", 
            "secondary_id": "2012-002664-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "Healthy volunteers low dose", 
                "intervention_name": "MRZ-99030 eye drops 5mg/mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Healthy volunteers high dose", 
                    "Glaucoma patients"
                ], 
                "intervention_name": "MRZ-99030 eye drops 20mg/mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo to MRZ-99030 eye drops", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrozoline"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "14050"
                }, 
                "name": "Parexel International GmbH, Early Phase Clinical Unit"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients", 
        "overall_official": {
            "affiliation": "Merz Pharmaceuticals GmbH", 
            "last_name": "Medical Expert", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 up to day 23"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 17"
            }, 
            {
                "measure": "Maximal plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to day 17"
            }
        ], 
        "source": "Merz Pharmaceuticals GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}